Text and Data Mining valid from 2019-04-03
First Online: 3 April 2019
Compliance with Ethical Standards
: This study was supported by KU Leuven and by the Fund on Market Analysis of Biologics and Biosimilars following Loss of Exclusivity (MABEL).
: SS, IH and AV have conducted biosimilar research sponsored by Hospira (now Pfizer). SS was involved in a stakeholder roundtable on biosimilars sponsored by Amgen, Pfizer and MSD and has participated in an advisory board meeting for Pfizer. SS currently works with Pfizer, and works with Celltrion as a consultant to carry out biosimilar research. AV is involved in consulting, advisory work and speaking engagements for a number of companies, including AbbVie, Accord, Amgen, Biogen, EGA, Pfizer/Hospira, Mundipharma, Roche and Sandoz. PD participated in advisory board meetings for AbbVie, Amgen and Hospira and is on the speakers’ bureaux of AbbVie, Celltrion, Hospira, Merck Serono and Roche. PT is employed by IQVIA™. EM has no conflicts of interest that are directly relevant to the content of this article. The statements, findings, conclusions, views, and opinions contained and expressed herein are not necessarily those of IQVIA™ or any of its affiliated or subsidiary entities.